Skip to main content
Chison Medical Technologies Co.,Ltd. logo

Chison Medical Technologies Co.,Ltd. — Investor Relations & Filings

Ticker · 688358 ISIN · CNE1000076R4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2022-10-27 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688358

About Chison Medical Technologies Co.,Ltd.

https://www.chison.com/

Chison Medical Technologies Co.,Ltd. specializes in the research, development, and manufacturing of diagnostic ultrasound systems. The company offers a comprehensive portfolio of medical imaging solutions, including trolley-based color Doppler systems, portable ultrasound units, and specialized handheld devices. Its products integrate advanced imaging technologies such as 4D imaging, artificial intelligence-assisted diagnostics, and high-resolution transducers to support clinical applications in cardiology, obstetrics, gynecology, and point-of-care settings. Chison focuses on delivering high-performance diagnostic tools to healthcare providers, supported by a global network of research centers and distribution channels. The company emphasizes continuous innovation in digital signal processing and transducer technology to enhance diagnostic accuracy and clinical workflow efficiency.

Recent filings

Filing Released Lang Actions
祥生医疗2022年股权激励计划首次授予部分激励对象名单（截止首次授予日）
Regulatory Filings Classification · 95% confidence The document is a list of recipients for a 2022 equity incentive plan (股权激励计划) with details on restricted stock allocations. It is an announcement of the initial grant of restricted stock to certain employees and management. There is no financial report, earnings data, or detailed management discussion. The document is short (531 characters) and serves as a notification of share-based compensation allocation. This fits best under a Regulatory Filing (RNS) as it is a general regulatory announcement about equity incentive allocation, not a full report or a capital change announcement (which would require new share issuance details).
2022-10-27 Chinese
《监事会议事规则》（2022年10月修订）
Governance Information Classification · 95% confidence The document is titled as the 'Supervisory Board Meeting Rules' of Wuxi Xiangsheng Medical Technology Co., Ltd. It details the procedures, powers, meeting protocols, and record-keeping rules for the supervisory board. There is no financial data, no report or announcement of financial results, no voting results, no management changes, no legal proceedings, no capital updates, and no investor presentation. The content is about internal governance rules specifically for the supervisory board, which is part of the company's governance structure. Therefore, this document fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 3536 characters, which is sufficient for a detailed governance document and not a brief announcement or certification. Hence, the classification is CGR with high confidence.
2022-10-27 Chinese
祥生医疗2022年第三季度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled '2022年第三季度报告' which translates to '2022 Third Quarter Report'. It contains detailed financial data including income statement, balance sheet, cash flow statement, and notes for the third quarter period ending September 30, 2022. The document explicitly states it is an unaudited quarterly report and includes comprehensive financial metrics and analysis for the quarter and year-to-date periods. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data. The document is not a brief announcement or a certification letter, and it is not an annual report or earnings release. Therefore, the correct classification is IR with high confidence. 9M 2022
2022-10-27 Chinese
祥生医疗关于召开2022年第三次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2022 third extraordinary general meeting of shareholders for Wuxi Xiangsheng Medical Technology Co., Ltd. It includes details about the meeting date, voting methods, agenda items, and proxy authorization. There are no financial statements or detailed financial data presented. The document is an announcement of a shareholder meeting and related procedural information, not a report or results announcement. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting and agenda rather than the voting results or solicitation materials, it is best classified as a Proxy Solicitation & Information Statement (PSI). The document length is under 5,000 characters and it is a meeting notice with agenda and proxy form, which aligns with PSI rather than DVA or AGM-R (which is for AGM materials).
2022-10-27 Chinese
上海荣正企业咨询服务（集团）股份有限公司关于无锡祥生医疗科技股份有限公司2022年限制性股票激励计划首次授予相关事项之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" related to the "2022 Restricted Stock Incentive Plan" for Wuxi Xiangsheng Medical Technology Co., Ltd. It discusses the approval procedures, grant conditions, grant details, and the impact of the stock incentive plan. The content is focused on the financial advisory opinion regarding the stock incentive plan and its compliance with relevant laws and regulations. It is not a full annual or interim financial report, nor is it a simple announcement or certification. The document is a detailed advisory report related to a capital incentive plan, which fits best under the category of Capital/Financing Update (CAP) as it relates to equity incentive plans and issuance of restricted stock. The document length (7697 characters) and detailed content confirm it is a full report, not just an announcement.
2022-10-27 Chinese
祥生医疗监事会关于公司2022年限制性股票激励计划首次授予部分激励对象名单的核查意见（截止首次授予日）
Regulatory Filings Classification · 95% confidence The document is a supervisory board opinion on the initial grant list of a 2022 restricted stock incentive plan for a company. It discusses compliance with laws and regulations regarding the eligibility of incentive recipients and confirms the grant date and price. This is a regulatory announcement related to stock incentive plans and does not contain financial statements or detailed financial data. It is not an annual report, audit report, earnings release, or other financial report. It is also not a management change or voting result announcement. The document is a formal announcement related to capital incentives but does not describe a capital raising or financing update. Given the nature and length of the document, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-10-27 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.